Lassa fever continues to threaten hundreds of thousands of lives across West Africa every year—yet, no licensed vaccine exists today. Strengthening Africa’s vaccine manufacturing and regulatory systems is essential to ensuring equitable access, long-term health security, and resilience against this growing public health challenge.
At the upcoming ECOWAS Lassa Conference side event, co-hosted by the Regionalised Vaccine Manufacturing Collaborative (RVMC) and the International Vaccine Institute (IVI), regional and global stakeholders will gather to chart a path forward. The session will spotlight opportunities to:
- Advance harmonization of regulatory frameworks through initiatives such as the African Medicines Agency (AMA) and AVAREF.
- Drive investment in local vaccine manufacturing capacity to ensure regional self-reliance.
- Foster inclusive collaboration across governments, research institutions, civil society organizations, and communities.
The 90-minute session will feature expert-led panel discussions, audience reflections, and a call to action, aiming to catalyze commitments for resilient vaccine systems, sustainable financing, and embedded community engagement throughout the vaccine R&D lifecycle.
We do hope you can join us!